Đăng xuất
Hypersecretory conditions
Adult: For the treatment of pathological conditions such as Zollinger-Ellison syndrome: 50 mg via IM or slow IV inj over 2 minutes or via intermittent IV infusion at a rate of 25 mg/hour for 2 hours. Dose may be repeated 6-8 hourly.
Intramuscular, Intravenous
Benign gastric ulcer, Duodenal ulcer
Adult: 50 mg via IM or slow IV inj over 2 minutes or via intermittent IV infusion at a rate of 25 mg/hour for 2 hours. Dose may be repeated 6-8 hourly.
Child: 6 months to 11 years Initially, 2 mg/kg or 2.5 mg/kg (Max: 50 mg) via slow IV inj over 10 minutes (either with a syringe pump followed by a 3 mL flush with NaCl 0.9% over 5 minutes or after dilution with NaCl 0.9% to 20 mL). Maintenance of pH >4: 1.5 mg/kg 6-8 hourly via intermittent IV infusion. Alternatively, 0.45 mg/kg via slow IV inj over 2 minutes as loading dose followed by 0.15 mg/kg/hour via continuous IV infusion; ≥12 years Same as adult dose.
Child: 6 months to 11 years Initially, 2 mg/kg or 2.5 mg/kg (Max: 50 mg) via slow IV inj over 10 minutes (either with a syringe pump followed by a 3 mL flush with NaCl 0.9% over 5 minutes or after dilution with NaCl 0.9% to 20 mL). Maintenance of pH >4: 1.5 mg/kg 6-8 hourly via intermittent IV infusion. Alternatively, 0.45 mg/kg via slow IV inj over 2 minutes as loading dose followed by 0.15 mg/kg/hour via continuous IV infusion; ≥12 years Same as adult dose.
Intramuscular, Intravenous
Prophylaxis of acid aspiration during general anaesthesia
Adult: 50 mg via IM or slow IV inj 45-60 minutes prior to induction of anaesthesia.
Intravenous
Prophylaxis of gastrointestinal haemorrhage from stress ulceration
Adult: 50 mg via slow IV inj as a priming dose, followed by 0.125-0.25 mg/kg/hour via continuous infusion. Continue treatment until oral feeding commences.
Oral
Postoperative peptic ulcer
Adult: 150 mg bid for at least 4 weeks.
Oral
Prophylaxis of acid aspiration during general anaesthesia
Adult: 150 mg given 2 hours prior to induction of anaesthesia and also when possible, a 150 mg dose given on the previous evening. Obstetric patients in labour: 150 mg may be given at the start of labour and may be repeated 6 hourly, as necessary.
Oral
Hypersecretory conditions
Adult: For the treatment of pathological conditions such as Zollinger-Ellison syndrome: 150 mg bid, may be administered more frequently in some cases. Doses up to 6,000 mg daily have been used. Dosages may be adjusted to individual patient needs and continued as long as clinically indicated.
Oral
Duodenal ulcers associated with H. pylori infection
Adult: 300 mg at bedtime or 150 mg bid given with oral amoxicillin and metronidazole for 2 weeks. Continue therapy without antibiotics for another 2 weeks. Patients who have responded to short-term therapy, particularly those with history of recurrent ulcers: Reduce maintenance treatment at a dose of 150 mg at bedtime.
Oral
NSAID-associated ulceration
Adult: 150 mg bid or 300 mg at bedtime for 8-12 weeks. For prophylaxis of NSAID-associated duodenal ulcers: 150 mg bid given concomitantly with NSAID treatment.
Oral
Chronic episodic dyspepsia
Adult: 150 mg bid for up to 6 weeks.
Oral
Prophylaxis of gastrointestinal haemorrhage from stress ulceration
Adult: 150 mg bid as a substitute for IV inj once oral therapy is possible.
Oral
Benign gastric ulcer, Duodenal ulcer
Adult: 150 mg bid or 300 mg at bedtime for at least 4 weeks. Maintenance: 150 mg daily at bedtime.
Child: 3-11 years 4-8 mg/kg daily in 2 divided doses for 4 weeks or up to 8 weeks if needed. Max: 300 mg daily; ≥12 years Same as adult dose.
Child: 3-11 years 4-8 mg/kg daily in 2 divided doses for 4 weeks or up to 8 weeks if needed. Max: 300 mg daily; ≥12 years Same as adult dose.
Oral
Gastro-oesophageal reflux disease
Adult: Symptomatic relief: 150 mg bid for 2 weeks; may be continued for a further 2 weeks in patients with inadequate response. Acute reflux oesophagitis: 150 mg bid or 300 mg at bedtime for up to 8 weeks or, if necessary, up to 12 weeks. Moderate to severe oesophagitis: 150 mg 4 times daily for up to 12 weeks. Long-term management of reflux oesophagitis: 150 mg bid.
Child: 3-11 years 5-10 mg/kg daily in 2 divided doses. Max: 600 mg daily; ≥12 years Same as adult dose.
Child: 3-11 years 5-10 mg/kg daily in 2 divided doses. Max: 600 mg daily; ≥12 years Same as adult dose.
